Friday, 10 June 2016

Disappointing results from opicinumab (anti-LINGO-1) study


Source MS Trust:


Preliminary results announced in a company report that opicinumab (also known as anti-LINGO-1 or BIIB033) failed to improve disability, assessed by a combination of physical and cognitive measures.  For more information click here.